Teva's $40.5 billion buyout of Allergan's generics business proved to be disastrous for the Israeli drugmaker, but now it has some extra cash to salve its wounds.Original Article
Settling a post-buyout hangover, Allergan gives Teva a $700M remedy
You may also like
Pharmaceutical Sales Customer Engagement –...
AstraZeneca’s Polyneuropathy Treatment Recommended...
Designing a Strategic Roadmap for Seamless Product...
AAPS PharmSci 360: LBFs and Tackling Oral Biologic...
CHMP Gives Positive Opinion to Novo Nordisk Hemophilia...
GSK, Cambridge to Partner on R&D for Kidney and...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.